Novel β-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy

References

• Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babe L, Senter PD, Fox JA, Schellenberger V. (2006). Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug Chem, 17: 410–418.
   PubMed Web of Science ®Google Scholar
• Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2: 750–763.
   PubMed Web of Science ®Google Scholar
• Bagshawe KD. (2009). Targeting: the ADEPT story so far. Curr Drug Targets, 10: 152–157.
   PubMed Web of Science ®Google Scholar
• Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. (1996). Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med, 2: 979–984.
   PubMed Web of Science ®Google Scholar
• Cartwright SJ, Waley SG. (1984). Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose. Biochem J, 221: 505–512.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. (2004). Efficient cancer therapy with a nanobody-based conjugate. Cancer Res, 64: 2853–2857.
   PubMed Web of Science ®Google Scholar
• Crown J, Pegram M. (2003). Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat, 79(Suppl. 1), S11–S18.
   PubMed Web of Science ®Google Scholar
• Cwirla SE, Peters EA, Barrett RW, Dower WJ. (1990). Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci U S A, 87: 6378–6382.
   PubMed Web of Science ®Google Scholar
• Dancey JE, Chen HX. (2006). Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov, 5: 649–659.
   PubMed Web of Science ®Google Scholar
• Denny WA, Wilson WR. (1998). The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol, 50: 387–394.
   PubMed Web of Science ®Google Scholar
• Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. (1998). Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res, 58: 2417–2425.
   PubMed Web of Science ®Google Scholar
• Fuchs H, Bachran C. (2009). Targeted tumor therapies at a glance. Curr Drug Targets, 10: 89–93.
   PubMed Web of Science ®Google Scholar
• Gao W, Xing B, Tsien RY, Rao J. (2003). Novel fluorogenic substrates for imaging beta-lactamase gene expression. J Am Chem Soc, 125: 11146–11147.
   PubMed Web of Science ®Google Scholar
• Hanessian S, Wang J. (1993). Design and synthesis of a cephalosporin-carboplatinum prodrug activable by a β-lactamase. Can J Chem, 71: 896–906.
   Web of Science ®Google Scholar
• Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, Viola W, Graycar T, Yeung VP, Aehle W, Meijer D, Wong S, Rashid MH, Valdes AM, Schellenberger V. (2005). A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther, 4: 1791–1800.
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. (2002). Overview of antibody phage-display technology and its applications. Methods Mol Biol, 178: 1–37.
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342.
   PubMed Web of Science ®Google Scholar
• Irving MB, Pan O, Scott JK. (2001). Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol, 5: 314–324.
   PubMed Web of Science ®Google Scholar
• Jones RN, Wilson HW, Novick WJ, Jr., BarryAL, Thornsberry C. (1982). In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent. J Clin Microbiol, 15: 954–958.
   PubMed Web of Science ®Google Scholar
• Kerr DE, Schreiber GJ, Vrudhula VM, Svensson HP, Hellstrom I, Hellstrom KE, Senter PD. (1995). Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res, 55: 3558–3563.
   PubMed Web of Science ®Google Scholar
• Kristensen P, Winter G. (1998). Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des, 3: 321–328.
   PubMedGoogle Scholar
• Kuhn D, Coates C, Daniel K, Chen D, Bhuiyan M, Kazi A, Turos E, Dou QP. (2004). Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci, 9: 2605–2617.
   PubMed Web of Science ®Google Scholar
• Mandava S, Makowski L, Devarapalli S, Uzubell J, Rodi DJ. (2004). RELIC—a bioinformatics server for combinatorial peptide analysis and identification of protein-ligand interaction sites. Proteomics, 4: 1439–1460.
   PubMed Web of Science ®Google Scholar
• Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ. (1997). Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol, 40: 189–201.
   PubMed Web of Science ®Google Scholar
• Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 6: 240–246.
   PubMedGoogle Scholar
• McDonagh CF, Beam KS, Wu GJ, Chen JH, Chace DF, Senter PD, Francisco JA. (2003). Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering. Bioconjug Chem, 14: 860–869.
   PubMed Web of Science ®Google Scholar
• Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, Briggs SL, Starling JJ. (1993). Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res, 53: 3956–3963.
   PubMed Web of Science ®Google Scholar
• Naik RR, Jones SE, Murray CJ, McAuliffe JC, Vaia RA, Stone MO. (2004). Peptide-templates for nanoparticle synthesis derived from PCR-driven phage display. Adv Func Mater, 14: 25–30.
   Web of Science ®Google Scholar
• Neri D, Bicknell R. (2005). Tumour vascular targeting. Nat Rev Cancer, 5: 436–446.
   PubMed Web of Science ®Google Scholar
• O’Callaghan CH, Morris A, Kirby SM, Shingler AH. (1972). Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother, 1: 283–288.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. (2005). Targeted therapy: wave of the future. J Clin Oncol, 23: 1776–1781.
   PubMed Web of Science ®Google Scholar
• Rigoutsos I, Floratos A. (1998). Combinatorial pattern discovery in biological sequences: the TEIRESIAS algorithm. Bioinformatics, 14: 55–67.
   PubMed Web of Science ®Google Scholar
• Rodi DJ, Soares AS, Makowski L. (2002). Quantitative assessment of peptide sequence diversity in M13 combinatorial peptide phage display libraries. J Mol Biol, 322: 1039–1052.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Presta LG, Kotts CE, Wirth C, Mordenti J, Osaka G, Wong WL, Nuijens A, Blackburn B, Carter P. (1995). Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res, 55: 63–70.
   PubMed Web of Science ®Google Scholar
• Senter PD, Springer CJ. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev, 53: 247–264.
   PubMed Web of Science ®Google Scholar
• Shukla GS, Krag DN. (2005a). Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library. Oncol Rep, 13: 757–764.
   PubMed Web of Science ®Google Scholar
• Shukla GS, Krag DN. (2005b). Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens. J Drug Target, 13: 7–18.
   PubMed Web of Science ®Google Scholar
• Shukla GS, Krag DN. (2006). Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin Biol Ther, 6: 39–54.
   PubMed Web of Science ®Google Scholar
• Shukla GS, Krag DN. (2009). Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection. J Mol Recognit, DOI:10.1002/jmr.957.
   PubMed Web of Science ®Google Scholar
• Shukla GS, Murray CJ, Estabrook M, Shen GP, Schellenberger V, Krag DN. (2007). Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells. Int J Cancer, 120: 2233–2242.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783–792.
   PubMed Web of Science ®Google Scholar
• Smith GP. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 228: 1315–1317.
   PubMed Web of Science ®Google Scholar
• Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM. (1995). In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res, 55: 2357–2365.
   PubMed Web of Science ®Google Scholar
• Szardenings M, Tornroth S, Mutulis F, Muceniece R, Keinanen K, Kuusinen A, Wikberg JE. (1997). Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1. J Biol Chem, 272: 27943–27948.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ito T, Furuta M, Eguchi C, Toda H, Wakabayashi-Takai E, Kaneko K. (2002). In situ phage screening. A method for identification of subnanogram tissue components in situ. J Biol Chem, 277: 30382–30387.
   PubMed Web of Science ®Google Scholar
• Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, Hoogenboom HR, Hufton SE. (2002). Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer, 101: 118–127.
   PubMed Web of Science ®Google Scholar
• Vrudhula VM, Svensson HP, Kennedy KA, Senter PD, Wallace PM. (1993). Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem, 4: 334–340.
   PubMed Web of Science ®Google Scholar
• Vrudhula VM, Svensson HP, Senter PD. (1995). Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates. J Med Chem, 38: 1380–1385.
   PubMed Web of Science ®Google Scholar
• Vrudhula VM, Kerr DE, Siemers NO, Dubowchik GM, Senter PD. (2003). Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein. Bioorg Med Chem Lett, 13: 539–542.
   PubMed Web of Science ®Google Scholar
• Xing B, Khanamiryan A, Rao J. (2005). Cell-permeable near-infrared fluorogenic substrates for imaging beta-lactamase activity. J Am Chem Soc, 127: 4158–4159.
   PubMed Web of Science ®Google Scholar
• Yao H, So MK, Rao J. (2007). A bioluminogenic substrate for in vivo imaging of beta-lactamase activity. Angew Chem Int Ed Engl, 46:7031–7034.
   PubMed Web of Science ®Google Scholar